Greystone Research Associates is pleased to announce the publication of a new
market study. Non-Insulin Diabetes Management: Products, Players, Markets
and Forecasts is a comprehensive evaluation and analysis of the
technology, products and participants providing the driving force behind this
evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug
developers, healthcare marketers, and supply chain participants with a
detailed understanding of the products, markets and commercial opportunities
for diabetes drug therapeutics that do not derive from the administration of
insulins or insulin analogs. Provider organization business managers,
healthcare administrators and investors will also benefit from this study.
The Growing Demand and Evolving Landscape for Diabetes Management
The diabetes market is changing. The convergence of environmental factors,
lifestyle factors and increased patient longevity are driving double-digit
growth projections for the incidence of non-insulin dependent (Type 2)
diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed
cases of diabetes and is increasingly being diagnosed in children and
adolescents. There are eight drug classes, analyzed in this report, with
proven efficacy for aiding in glycemic control in this patient population.
Because of the size and business potential of this market, pipeline activity
is high. In addition to derivative products and products that combine approved
APIs in a single dosage form, drugs based on newer chemistries and mechanisms
that include amylin analogs and GLP-1 drugs have been introduced. Globally,
revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011
and 2016. Safety issues associated with post-launch-reported events will
continue to be a major concern for market participants.
- Analyzes and evaluates non-insulin or insulin analog drug products and development-stage candidates for glycemic control
- Provides assessments of diabetes managemnet markets for non-insulin drugsl and examines key market and commercialization factors
- Evaluates the impact of economic, technology, and regulatory factors on diabetes management markets
- Provides market data and forecasts to 2016
- Profiles market sector participants, their product development activities and business strategies
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.